Azithromycin for Child Survival in Niger: Mortality and Resistance Trial
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old
reduced child mortality. The World Health Organization (WHO) released conditional guidelines
for this intervention, which include targeting azithromycin distributions to children 1-11
months of age in high mortality settings.Targeting treatment to children 1-11 months old
could reduce antimicrobial resistance by limiting antibiotic distributions while treating
children at the highest mortality risk. However, this targeted intervention has not yet been
tested.
The AVENIR mortality/resistance trial aims to assess the efficacy of age-based targeting of
biannual azithromycin distribution on mortality as well as determine the impact of age-based
targeting on antimicrobial resistance.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Helen Keller International Ministry of Health, Niger